Abdullah M. Khan, MBBS, discusses the pivotal phase 3 KarMMa-3 trial of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Abdullah M. Khan, MBBS
Advertisement
Abdullah M. Khan, MBBS, is a hematologist specializing in multiple myeloma and related plasma cell disorders. He received his MBBS at Aga Khan University in Karachi, Pakistan, and completed his internal medicine and chief medical residencies at Rutgers – New Jersey Medical School. More recently, he completed his fellowship in hematology and oncology at the University of Florida.
Articles by Abdullah M. Khan, MBBS
Abdullah M. Khan, MBBS, discusses the recent updates to data on the use of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
